BIO-Europe Spring 2026: In conversation with Robert Jacks
R&D
At BIO-Europe Spring 2026 in Lisbon, Portugal web editor Nicole Raleigh sat down with Robert Jacks, CEO of Sparrow Pharmaceuticals, for a conversation on the company’s work in the cardiometabolic space.
That includes Sparrow’s lead candidate clofutriben, a once-daily, oral HSD-1 inhibitor. From the importance of regulating local cortisol production to a future world of GLP-1 agonists – here’s a sneak peek at the conversations happening at the BIO-Europe Spring conference this year.
And keep an eye on our Spotlight On page for other content updates.
